Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 18, Issue 26, 2012, Pages 3426-3434

  Baek, Yang Hyun ^a   Kim, Kyoung Tae ^a   Lee, Sung Wook ^a   Jeong, Jin Sook ^a   Park, Byeong Ho ^a   Nam, Kyung Jin ^a   Cho, Jin Han ^a   Kim, Young Hoon ^a   Roh, Young Hoon ^a   Lee, Hyung Sik ^a   Choi, Young Min ^a   Han, Sang Young ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

Advanced hepatocellular carcinoma; Child pugh classification; Floxuridine; Hepatic arterial infusion chemotherapy; Portal vein tumor thrombus

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; DEXAMETHASONE; FLOXURIDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CATHETER INFECTION; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DUODENUM ULCER; FEMALE; HEPATIC ARTERY; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PEPTIC ULCER; PORTAL VEIN THROMBOSIS; PROGRESSION FREE SURVIVAL; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; SIDE EFFECT; STOMACH ULCER; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR THROMBUS; UREA NITROGEN BLOOD LEVEL;

EID: 84863952174     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i26.3426     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156
2. Lee JS. Advances in the treatment of hepatocellular carcinoma. Korean J Med 2009; 77: 290-297
3. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for he-patocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 145-151
4. Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet 1985; 161: 346-350
5. Ohtomo K, Furui S, Kokubo T, Yamauchi T, Itai Y, Yashiro N, Iio M. Transcatheter arterial embolization (TAE) in treatment for hepatoma--analysis of three-year survivors. Radiat Med 1985; 3: 176-180
6. Shiina S, Tagawa K, Niwa Y, Unuma T, Komatsu Y, Yo-shiura K, Hamada E, Takahashi M, Shiratori Y, Terano A. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR Am J Roentgenol 1993; 160: 1023-1028
7. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, Miller CM, Schwartz ME. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235: 533-539
8. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171
9. Chuang VP. Hepatic tumor angiography: a subject review. Radiology 1983; 148: 633-639
10. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-595
11. Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, Steele G, Frei E. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fuoro-2'-deoxyuridine and 5-fuorouracil. Cancer Res 1978; 38: 3784-3792
12. Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 1983; 10: 176-182
13. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, Ito K. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002; 80: 143-148
14. Oberfeld RA, Sampson E, Heatley GJ. Hepatic artery infusion chemotherapy for metastatic colorectal cancer to the liver at the lahey clinic: comparison between two methods of treatment, surgical versus percutaneous catheter placement. Am J Clin Oncol 2004; 27: 376-383
15. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15: 3210-3216
16. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401
17. Bismuth H, Morino M, Sherlock D, Castaing D, Miglietta C, Cauquil P, Roche A. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 1992; 163: 387-394
18. Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs 2004; 15: 427-437
19. Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC. Hepatic arterial infusion chemotherapy using high-dose 5-fuo-rouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol 2009; 44:1477-1486
20. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M. Combination therapy of intraarterial 5-fuorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-1997
21. American Society of Clinical Oncology. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16: 301-308
22. Clavien PA, Selzner N, Morse M, Selzner M, Paulson E. Downstaging of hepatocellular carcinoma and liver metas-tases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002; 131: 433-442
23. Patt YZ, Charnsangavej C, Yoffe B, Smith R, Lawrence D, Chuang V, Carrasco H, Roh M, Chase J, Fischer H. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 1994; 12: 1204-1211
24. Skitzki JJ, Chang AE. Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. Surg Oncol 2002; 11: 123-135
25. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated non surgical hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 1995-2004
26. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Ef-fcacy and safety of sorafenib in patients in the Asia-Pacifc region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34
27. Seno H, Ito K, Kojima K, Nakajima N, Chiba T. Efficacy of an implanted drug delivery system for advanced hepatocel-lular carcinoma using 5-fuorouracil, epirubicin and mitomycin C. J Gastroenterol Hepatol 1999; 14: 811-816
28. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kiriyama S, Suga T, Takahashi M. The efficacy of continuous local arterial infusion of 5-fuorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 1995; 52: 295-299
29. Takizawa D, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, Katakai K, Kojima A, Matsuzaki Y, Mori M. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci 2007; 52: 3290-3295
30. Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Glória H, Marinho R, Távora I, Ramalho F, de Moura MC. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int 2006; 26: 680-687
31. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-67
32. Cheong JY, Lee KM, Cho SW, Won JH, Kim JK, Wang HJ, Hahm KB, Kim JH. Intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein thrombosis. Korean J Med 2004; 67: 40-48
33. Jarnagin WR, Schwartz LH, Gultekin DH, Gönen M, Havi-land D, Shia J, D'Angelica M, Fong Y, Dematteo R, Tse A, Blumgart LH, Kemeny N. Regional chemotherapy for un-resectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009; 20: 1589-1595
34. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
35. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603
36. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 2010; 53: 126-131
37. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010; 102: 981-986
38. Kemeny N, Seiter K, Niedzwiecki D, Chapman D, Sigurd-son E, Cohen A, Botet J, Oderman P, Murray P. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992; 69: 327-334
39. Kemeny N, Conti JA, Cohen A, Campana P, Huang Y, Shi WJ, Botet J, Pulliam S, Bertino JR. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for un-resectable liver metastases from colorectal carcinoma. J Clin Oncol 1994; 12: 2288-2295
40. Boublil JL, Milano G, Khater R, Bourry J, Thyss A, Brune-ton JN, Renée N, Philip C, Namer M. Continuous 5-day regional chemotherapy by 5-fuorouracil in colon carcinoma: pharmacokinetic evaluation. Br J Cancer 1985; 52: 15-20